세균 및 바이러스 검체 채취 시장 예측(2026-2032년)

The Bacterial & Viral Specimen Collection Market is projected to grow by USD 39.76 billion at a CAGR of 12.40% by 2032.

Bacterial and viral specimen collection is a critical front-end function in infectious disease diagnostics, antimicrobial stewardship, outbreak investigation, blood safety, respiratory surveillance, sexually transmitted infection testing, and hospital infection prevention. The quality of swabs, transport media, blood culture bottles, urine containers, stool collection kits, nasopharyngeal and oropharyngeal sampling devices, saliva collection systems, and viral transport media directly influences analytical accuracy, turnaround time, biosafety, and clinical decision-making. Demand is shaped by recurring respiratory virus seasons, tuberculosis and sexually transmitted infection control programs, hospital-acquired infection monitoring, foodborne and waterborne disease surveillance, and public health preparedness following the COVID-19 pandemic. Regulatory emphasis on specimen integrity, traceability, cold-chain management, pre-analytical quality control, and validated transport conditions is strengthening procurement standards across hospitals, reference laboratories, point-of-care settings, community testing sites, and home-based collection pathways. The sector is also being reshaped by molecular diagnostics, multiplex PCR, sequencing-based epidemiology, antimicrobial resistance surveillance, and digital sample tracking, all of which require reliable collection workflows from patient to laboratory.

Transformative Shifts in the Specimen Collection Landscape

The specimen collection landscape is shifting from fragmented, manual, and site-dependent practices toward standardized, digitally traceable, and decentralized collection models. The pandemic accelerated acceptance of self-collection, drive-through sampling, saliva-based testing, and rapid deployment logistics, while also exposing vulnerabilities in swab supply, transport media availability, cold-chain capacity, and workforce training. Health systems are now prioritizing resilient supply chains, prefilled and ready-to-use collection kits, barcoded specimen containers, tamper-evident packaging, and biosafety-compliant transport aligned with clinical laboratory and public health requirements. Another major shift is the move from single-pathogen testing toward syndromic and multiplex diagnostic panels, which increases the need for specimen types and media compatible with nucleic acid amplification, antigen testing, culture, and sequencing. Sustainability is also becoming a procurement consideration as laboratories seek to reduce single-use plastic waste without compromising sterility, sample stability, or infection control. At the same time, decentralized testing in urgent care, pharmacies, schools, workplaces, and home settings is pushing manufacturers and healthcare providers to simplify instructions, improve sample adequacy, and reduce collection errors through ergonomic devices and digital guidance.

Cumulative Impact of Artificial Intelligence on Specimen Collection

Artificial intelligence is beginning to influence bacterial and viral specimen collection by improving workflow design, sample triage, logistics planning, and quality assurance rather than replacing the biological collection step itself. AI-enabled demand planning can help anticipate seasonal surges in respiratory specimens, optimize inventory allocation for swabs and transport media, and reduce stockout risks during outbreaks. In laboratory networks, machine learning can support accessioning prioritization by combining test orders, patient risk indicators, location data, and outbreak signals to route specimens more efficiently. Computer vision and automation can assist with labeling verification, tube identification, leakage detection, and chain-of-custody checks, reducing pre-analytical errors that are widely recognized contributors to diagnostic inaccuracy. AI-driven epidemiological surveillance can integrate specimen metadata with test positivity patterns, wastewater signals, and genomic sequencing outputs to detect emerging clusters earlier. In patient-facing settings, digital assistants can guide self-collection, confirm kit completion, and reduce invalid samples by providing step-by-step instructions. These applications must be governed by data privacy safeguards, bias monitoring, cybersecurity controls, and validation against clinical performance requirements, particularly when AI informs triage, outbreak response, or public health reporting.

Key Regional Insights Across Global Specimen Collection Markets

Asia-Pacific is characterized by large population bases, dense urban centers, expanding molecular diagnostics infrastructure, and persistent surveillance needs for respiratory viruses, tuberculosis, dengue, enteric pathogens, and antimicrobial resistance, making specimen collection reliability central to both clinical care and public health monitoring. North America benefits from mature laboratory networks, extensive hospital infection control programs, strong public health reporting infrastructure, and broad adoption of molecular and point-of-care testing, which supports demand for standardized collection kits, digital labeling, and validated transport systems. Latin America faces a dual requirement: strengthening routine infectious disease diagnostics while maintaining readiness for arboviruses, influenza, COVID-19, tuberculosis, and foodborne disease investigations; this creates emphasis on durable logistics, cost-effective collection formats, and improved access outside major urban laboratories. Europe is shaped by stringent quality systems, harmonized public health surveillance initiatives, antimicrobial resistance action plans, and increasing use of genomic epidemiology, all of which require consistent specimen quality and traceable pre-analytical workflows across borders. The Middle East is investing in healthcare modernization, travel-related disease preparedness, and hospital infection prevention, with specimen collection needs linked to high patient mobility, pilgrimage-related surveillance, and expanding laboratory capacity. Africa presents significant opportunities for improved specimen collection in tuberculosis, HIV-related opportunistic infections, malaria differential diagnosis, viral hemorrhagic fever preparedness, respiratory disease surveillance, and antimicrobial resistance monitoring, while also requiring solutions that withstand transport delays, heat exposure, limited cold-chain access, and variable laboratory reach.

Key Group Insights Shaping Bacterial & Viral Specimen Collection

ASEAN countries are strengthening infectious disease surveillance after repeated experiences with respiratory outbreaks, dengue, tuberculosis, and emerging zoonotic threats, driving interest in scalable specimen collection kits, community sampling, and cross-border laboratory coordination. The GCC is shaped by high investment in healthcare infrastructure, medical tourism, mass gathering surveillance, and hospital infection control, supporting adoption of standardized bacterial and viral sample collection workflows that align with biosafety and traceability expectations. The European Union emphasizes harmonized laboratory quality, antimicrobial resistance monitoring, cross-border outbreak intelligence, and data-driven public health coordination, which reinforces the importance of validated transport media, specimen stability, and interoperable digital tracking. BRICS economies combine large populations, diverse disease burdens, expanding domestic diagnostics capabilities, and active public health programs for tuberculosis, respiratory viruses, enteric infections, and antimicrobial resistance, creating a broad need for affordable, robust, and high-throughput specimen collection solutions. G7 countries generally operate advanced laboratory networks with strong regulatory oversight, sequencing capacity, and pandemic preparedness planning, making them early adopters of automated accessioning, self-collection validation, and integrated sample logistics. NATO member countries place additional emphasis on biosecurity, deployable medical readiness, force health protection, and coordinated infectious disease surveillance, which supports requirements for secure transport, chain-of-custody documentation, and resilient collection supply chains in both civilian and defense health settings.

Key Country Insights for Specimen Collection Strategies

The United States has extensive clinical laboratory capacity, strong infectious disease reporting systems, and broad use of molecular diagnostics, supporting continued emphasis on respiratory swabs, blood culture collection, STI sampling, and home-based specimen pathways. Canada's specimen collection priorities are shaped by public health surveillance, remote and Indigenous community access, respiratory virus monitoring, and the need for transport systems that perform across long distances and varied climates. Mexico is advancing laboratory access for respiratory infections, tuberculosis, gastrointestinal pathogens, and antimicrobial resistance, with specimen collection needs tied to urban hospital networks and broader community testing reach. Brazil's large public health system, arbovirus surveillance, tuberculosis burden, and genomic monitoring programs create demand for scalable specimen collection logistics across geographically diverse regions. The United Kingdom continues to emphasize respiratory virus surveillance, antimicrobial resistance programs, genomic epidemiology, and decentralized testing models, making sample integrity and digital traceability key priorities. Germany's strong laboratory infrastructure, hospital quality standards, and infection prevention programs support rigorous bacterial culture collection, viral molecular testing, and specimen transport compliance. France combines national surveillance programs, hospital infection control, and molecular diagnostics expansion, reinforcing demand for validated collection systems across clinical and public health laboratories. Russia's infectious disease monitoring needs include respiratory viruses, tuberculosis, and regional outbreak preparedness, requiring specimen handling systems suited to broad geography and variable logistics. Italy and Spain maintain strong hospital laboratory networks and seasonal respiratory surveillance, with specimen collection strategies increasingly shaped by antimicrobial resistance, aging populations, and outpatient diagnostics. China has expanded molecular testing capacity, respiratory pathogen surveillance, and public health laboratory infrastructure, increasing attention to high-throughput collection, transport, and sample tracking. India faces large-scale needs across tuberculosis, respiratory infections, enteric disease, antimicrobial resistance, and decentralized diagnostics, making affordable, stable, and easy-to-use collection formats particularly important. Japan's aging population, robust laboratory quality culture, and respiratory disease monitoring support precise specimen workflows and validated transport conditions. Australia's geographically dispersed population and strong public health surveillance require collection systems suitable for metropolitan hospitals, regional clinics, and remote communities. South Korea's advanced diagnostics ecosystem, outbreak response experience, and digital health capabilities support efficient specimen logistics, rapid testing pathways, and high-quality viral and bacterial sampling practices.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize pre-analytical quality as a core differentiator by investing in validated collection devices, stable transport media, leakage-resistant packaging, clear instructions, and compatibility with culture, antigen testing, PCR, multiplex panels, and sequencing. Organizations should strengthen supply-chain resilience through dual sourcing, regional inventory buffers, demand-sensing systems, and outbreak-responsive distribution models. Expanding self-collection and near-patient collection requires human-centered kit design, multilingual instructions, digital guidance, and mechanisms to confirm sample adequacy before laboratory processing. Leaders should also align product development with antimicrobial resistance surveillance, respiratory pathogen monitoring, sexually transmitted infection programs, and hospital infection prevention, where specimen quality directly affects clinical and public health outcomes. Digital traceability should be embedded from collection through transport and accessioning using barcodes, electronic requisitions, chain-of-custody tools, and laboratory information system interoperability. To meet global procurement expectations, manufacturers and healthcare providers should document sterility, biosafety, stability, storage conditions, and usability evidence while exploring lower-waste materials and packaging strategies that do not compromise performance.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in publicly available and verifiable sources, including public health agency guidance, laboratory standards, peer-reviewed literature, infectious disease surveillance publications, regulatory documentation, clinical laboratory best practices, and health system policy materials. The analysis focuses on qualitative evidence related to specimen collection workflows, pre-analytical quality, transport requirements, diagnostic compatibility, regional disease surveillance priorities, and healthcare infrastructure trends. Insights are synthesized through thematic review across bacterial culture, viral transport, molecular diagnostics, antimicrobial resistance monitoring, outbreak response, and decentralized testing environments. The methodology excludes market sizing, market share, revenue estimation, and forecasting, instead emphasizing operational, regulatory, technological, and public health factors that influence adoption and implementation. Regional, group, and country-level observations are evaluated by considering disease burden patterns, laboratory capacity, surveillance priorities, logistics constraints, and documented health system initiatives.

Conclusion

Bacterial and viral specimen collection is becoming a strategic foundation for accurate diagnostics, resilient outbreak response, antimicrobial resistance surveillance, and decentralized healthcare delivery. The sector is evolving beyond basic sample containers and swabs toward integrated collection ecosystems that combine validated materials, biosafety, digital traceability, self-collection usability, and compatibility with advanced diagnostic platforms. Artificial intelligence, automation, and data-driven logistics are strengthening sample quality and operational efficiency, while regional differences in disease burden, infrastructure, and public health priorities continue to shape adoption pathways. Organizations that focus on specimen integrity, scalable distribution, regulatory compliance, and user-centered design will be best positioned to support laboratories, healthcare providers, and public health authorities in improving infectious disease detection and response without compromising quality or safety.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Bacterial & Viral Specimen Collection Market, by Specimen Type

• 7.1. Introduction
• 7.2. Bacterial
  • 7.2.1. Blood
  • 7.2.2. Urine
  • 7.2.3. Wound
• 7.3. Viral
  • 7.3.1. Blood
  • 7.3.2. Nasopharyngeal Swab
  • 7.3.3. Saliva

8. Bacterial & Viral Specimen Collection Market, by Product

• 8.1. Introduction
• 8.2. Collection Kit
• 8.3. Collection Tube
  • 8.3.1. Nonvacuum Tube
  • 8.3.2. Vacuum Tube
• 8.4. Swab
  • 8.4.1. Cotton Swab
  • 8.4.2. Flocked Swab
  • 8.4.3. Foam Swab
• 8.5. Transport Media
  • 8.5.1. Bacterial Transport Media
  • 8.5.2. Viral Transport Media

9. Bacterial & Viral Specimen Collection Market, by Technology

• 9.1. Introduction
• 9.2. Automated
• 9.3. Manual

10. Bacterial & Viral Specimen Collection Market, by End User

• 10.1. Introduction
• 10.2. Clinics
• 10.3. Diagnostic Centers
• 10.4. Hospitals
• 10.5. Laboratories

11. Bacterial & Viral Specimen Collection Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Offline
• 11.3. Online

12. Bacterial & Viral Specimen Collection Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Bacterial & Viral Specimen Collection Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Bacterial & Viral Specimen Collection Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Avantor, Inc.
• 16.2. Becton, Dickinson, and Company
• 16.3. bioMerieux S.A.
• 16.4. Cardinal Health
• 16.5. Copan Group
• 16.6. DiaSorin S.p.A.
• 16.7. Dynarex Corporation
• 16.8. Greiner Bio-One International GmbH
• 16.9. Hardy Diagnostics
• 16.10. HiMedia Laboratories Pvt. Ltd
• 16.11. Longhorn Vaccines and Diagnostics, LLC
• 16.12. Lucence Diagnostics Pte Ltd
• 16.13. Medical Wire & Equipment
• 16.14. Medline Industries, LP.
• 16.15. Meridian Bioscience, Inc
• 16.16. Miraclean Technology Co., Ltd
• 16.17. Pretium Packaging
• 16.18. Puritan Medical Products
• 16.19. QuidelOrtho Corporation
• 16.20. Stellar Scientific
• 16.21. Thermo Fisher Scientific, Inc.
• 16.22. Titan Biotech Ltd.
• 16.23. Trinity Biotech PLC
• 16.24. Vircell, S.L.
• 16.25. Wuxi Nest Biotechnology Co., Ltd.